Skip to main content

Genome Editing and the Future of Personalized and Targeted Cancer Medicine

vchalup / stock.adobe.com © vchalup / stock.adobe.com

Many human diseases, including cancer, have their etiology in genome alterations. Completion of the human genome project and the development of next generation sequencing technologies with single cell resolution will lead to routine complete genome mapping of cancer patients in the future. Genome editing is based on unique properties shared by mega-nucleases, zinc-finger nucleases, transcription activator-like effector nucleases, and the CRISPR/Cas9 system and their ability to generate cuts in the human genome at specific targeted sites thereby allowing replacement of defective DNA with a corrected sequence. Although still in its infancy, these technologies have the potential to revolutionize medicine and patient care.

Molecular Cancer is excited to present a series of original research and review articles related to genome editing and reprogramming.

Open for submission. Submission window closes 15th December 2021.

  1. The 2020 Nobel Prize in Chemistry was awarded to Emmanuelle Charpentier and Jennifer Doudna for the development of the Clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease9 (CRI...

    Authors: Huimin Zhang, Chunhong Qin, Changming An, Xiwang Zheng, Shuxin Wen, Wenjie Chen, Xianfang Liu, Zhenghua Lv, Pingchang Yang, Wei Xu, Wei Gao and Yongyan Wu

    Citation: Molecular Cancer 2021 20:126

    Content type: Review

    Published on: